Book Value per Share: Biomea Fusion, Inc. (BMEA)

Graphic logo of Biomea Fusion, Inc. (BMEA)

This chart of Biomea Fusion, Inc. (BMEA) price action, whose metric stands at 0.17, reflects the business dynamics of combating metabolic disorders. Biomea Fusion, Inc. (BMEA) is optimizing supply chains for testing to minimize resource shortage risks. Success depends on the approval of diabetes and oncology therapies, as well as patent protection. A neutral geopolitical backdrop and the humanitarian status of medicine ensure stability.

Biomea Fusion Inc (BMEA): Share Book Value from 07/04/2022 to 10/27/2026

biomeafusion.com - analytical breakdowns and key metrics (BMEA)

- price and consensus price forecast:
Stock Price Biomea|BMEA - Average Forecast Price
- market capitalization data:
Market Capitalization Biomea Fusion, Inc.|BMEA - Enterprise Value
- book capitalization data:
Net Assets per Single Share Biomea Fusion|BMEA - Net Asset Value|Market Capitalization to Book Value Ratio biomeafusion.com|BMEA - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Biomea Fusion, Inc.|BMEA - Long-Term Debt to Capital|Short-Term Debt to Equity Biomea Fusion|BMEA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Biomea Fusion, Inc.
Fundamental company valuation:Biomea - BMEA
Manufactured products of Biomea Fusion

Biomea Fusion, Inc. (BMEA) is developing an innovative small-molecule platform for oncology and diabetes therapies, where capitalization depends on the success of clinical trials. The digitization of net assets via the book value per share on GURU.Markets reflects the real value of an investor's stake net of liabilities, allowing for an assessment of the company's internal reserves and the risk of overpayment through the stepped dynamics of 10-Q reports.

Competitors of Biomea Fusion, Inc. (BMEA)

ASND (Ascendis Pharma Inc.) - Book Value per Share|MDGL - Net Asset Value per Share|CORT: Book Value per Share|RYTM (rhythmtx.com) - Book Value per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Accounting Value per Share|Accounting Value of a Share MBX (MBX Biosciences, Inc.)|Altimmune Corp - Net Assets per Single Share|Accounting Value per Share Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Value per Share|bioagelabs.com (BIOA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS